TWA
KYMR icon

TCI Wealth Advisors’s Kymera Therapeutics KYMR Stock Holding History

TCI Wealth Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-236
Closed -$6.99K – 1284
2023
Q1 		$6.99K Hold
236
– – ﹤0.01% 1303
2022
Q4 		$5.89K Hold
236
– – ﹤0.01% 1414
2022
Q3 		$5K Hold
236
– – ﹤0.01% 1476
2022
Q2 		$5K Buy
+236
New +$5.51K ﹤0.01% 1501
2022
Q1 		– Sell
-90
Closed -$6K – 2341
2021
Q4 		$6K Buy
90
+29
+48% +$1.69K ﹤0.01% 1545
2021
Q3 		$4K Buy
61
+15
+33% +$870 ﹤0.01% 1771
2021
Q2 		$2K Buy
+46
New +$2K ﹤0.01% 2036

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCI Wealth Advisors's KYMR Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Kymera Therapeutics (KYMR) in Q2 2023, closing a stake of 236 shares — an estimated $6.99K sold.

TCI Wealth Advisors first reported a position in KYMR in Q2 2021 and held it in 7 quarters. The position peaked at $6.99K in Q1 2023. 128 funds tracked by Wall St. Rank hold KYMR as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Kymera Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 236 Kymera Therapeutics shares in Q2 2023, an estimated $6.99K.
  • TCI Wealth Advisors first reported a position in Kymera Therapeutics in Q2 2021 and held it in 7 quarters.
  • TCI Wealth Advisors's Kymera Therapeutics position peaked at $6.99K in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.